{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T22:48:03Z","timestamp":1780786083802,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/tp.0000000000001605","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T14:33:27Z","timestamp":1481121207000},"page":"1001-1008","source":"Crossref","is-referenced-by-count":13,"title":["Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C\u2013Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma"],"prefix":"10.1097","volume":"101","author":[{"given":"James","family":"Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210211","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/jlts.2001.27088","article-title":"Transplantation of hepatitis C\u2013positive livers in hepatitis C\u2013positive patients is equivalent to transplanting hepatitis C\u2013negative livers","volume":"7","author":"Marroquin","year":"2001","journal-title":"Liver Transpl"},{"key":"R2-21-20210211","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.transproceed.2005.06.004","article-title":"Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience","volume":"37","author":"Ricchiuti","year":"2005","journal-title":"Transplant Proc"},{"key":"R3-21-20210211","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1034\/j.1600-6143.2003.00189.x","article-title":"Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis","volume":"3","author":"Saab","year":"2003","journal-title":"Am J Transplant"},{"key":"R4-21-20210211","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/j.1432-2277.2010.01092.x","article-title":"Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis","volume":"23","author":"Northup","year":"2010","journal-title":"Transpl Int"},{"key":"R5-21-20210211","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"R6-21-20210211","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R7-21-20210211","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R8-21-20210211","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/lt.500040401","article-title":"Cholestatic hepatitis C in liver allografts","volume":"4","author":"Taga Scott","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"R9-21-20210211","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/lt.22175","article-title":"Post\u2013liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria","volume":"16","author":"Narang","year":"2010","journal-title":"Liver Transpl"},{"key":"R10-21-20210211","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"R11-21-20210211","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"Bruno","year":"2016","journal-title":"J Hepatol"},{"key":"R13-21-20210211","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R14-21-20210211","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/ajt.12581","article-title":"OPTN\/SRTR 2012 annual data report: liver","volume":"14","author":"Kim","year":"2014","journal-title":"Am J Transplant"},{"key":"R15-21-20210211","doi-asserted-by":"crossref","first-page":"44","DOI":"10.12659\/AOT.892530","article-title":"Donor hepatitis C sero-status does not impact survival in liver transplantation","volume":"20","author":"Montenovo","year":"2015","journal-title":"Ann Transplant"},{"key":"R16-21-20210211","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hec.787","article-title":"An empirical comparison of EQ-5D and SF-6D in liver transplant patients","volume":"12","author":"Longworth","year":"2003","journal-title":"Health Econ"},{"key":"R17-21-20210211","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre\u2013 and post\u2013liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transpl"},{"key":"R18-21-20210211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hep.27135","article-title":"Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria","volume":"61","author":"Lim","year":"2015","journal-title":"Hepatology"},{"key":"R19-21-20210211","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.13320","article-title":"Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis","volume":"15","author":"Cortesi","year":"2015","journal-title":"Am J Transplant"},{"key":"R23-21-20210211","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2008.07.029","article-title":"The burden of illness associated with hepatocellular carcinoma in the United States","volume":"50","author":"Lang","year":"2009","journal-title":"J Hepatol"},{"key":"R24-21-20210211","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.27151","article-title":"Cost analysis of sofosbuvir\/ribavirin versus sofosbuvir\/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible\/intolerant individuals","volume":"60","author":"Hagan","year":"2014","journal-title":"Hepatology"},{"key":"R25-21-20210211","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12876-015-0320-4","article-title":"Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US","volume":"15","author":"Zhang","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"R26-21-20210211","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/cncr.29855","article-title":"Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis","volume":"122","author":"Tapper","year":"2016","journal-title":"Cancer"},{"key":"R27-21-20210211","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.28430","article-title":"The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics","volume":"63","author":"Rein","year":"2016","journal-title":"Hepatology"},{"key":"R28-21-20210211","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/apt.13798","article-title":"Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis","volume":"44","author":"Njei","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-21-20210211","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/tri.12591","article-title":"Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation","volume":"28","author":"Vitale","year":"2015","journal-title":"Transpl Int"},{"key":"R31-21-20210211","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000001605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:27:06Z","timestamp":1620977226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201705000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000001605","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}